The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The launch coincides with IBS Awareness Month in April
The trial also demonstrated significant improvements across multiple secondary endpoints
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Subscribe To Our Newsletter & Stay Updated
